Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leading rare disease company, announces the successful completion of its acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. With the completion of the acquisition, Mirum adds worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody for chronic hepatitis delta virus (HDV), a rare and severe liver disease with no FDA-approved therapies in the United States. Brelovitug has received Breakthrough Therapy designation from the FDA and PRIME designation from the European Medicines Agency and is currently being evaluated in the global AZURE Phase 3 registrational program.
Read the full article: Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease //
Source: https://www.businesswire.com/news/home/20260126610526/en/Mirum-Pharmaceuticals-Completes-Acquisition-of-Bluejay-Therapeutics-Expanding-Global-Leadership-in-Rare-Disease